EATONTOWN, NJ, 5 September, 2011 — Hikma Pharmaceuticals, PLC, (LON: HIK)(Nasdaq Dubai: HIK) and its wholly‐owned subsidiary, West‐Ward Pharmaceuticals, today announced the US launch of therapeutic heparin in single‐ and multiple‐dose vials.
5 September 2011
Heparin is used to prevent clot formation in central venous catheters and for anticoagulant (blood thinning) therapy, and is available in numerous delivery systems for different modes of administration. Hikma’s five new vial presentations of heparin range in volume from 1 milliliter (mL) to 30 mL, and in concentration from 1,000 units per mL to 10,000 units per mL.
Hikma recognizes the clinical need for this important medication and is pleased to be introducing this high-quality, US manufactured product in which all porcine derived materials are exclusively from the US and Canada.